#New York #Class Action #Levi & Korsinsky #Nano-X Imaging

Legal Action for Nano-X Imaging Investors

On July 15, 2026, law firm Levi & Korsinsky, LLP announced the initiation of a class action lawsuit targeting Nano-X Imaging Ltd. (NASDAQ: NNOX) aimed at recovering losses for investors who purchased shares between March 31, 2025, and April 17, 2026. This move follows a significant decline in NNOX’s stock price, which plummeted 24.39% after the company disclosed serious manufacturing issues.

Background on Nano-X and the Class Period

Nano-X Imaging has been involved in revolutionizing medical imaging technology. However, their financial reports raised eyebrows after the company revealed an impairment charge of $17.5 million associated with its South Korean manufacturing facility, coupled with a transition to outsourcing production. Following these disclosures on April 20, 2026, NNOX shares fell to $2.155 from a previous high when it explored strong growth avenues.

The law firm clarifies that investors who felt misled during this time are invited to ascertain their eligibility for the class action suit. The primary focus is the alleged lack of vital information disclosed in the company's SEC filings throughout the class period.

The Missing Elements from SEC Filings

Levi & Korsinsky's allegations highlight critical oversights in Nano-X's reporting:

• - Material Risk Factors: According to Item 105 of Regulation S-K, the company was obligated to declare significant elements that may make the securities speculative, yet it failed to reveal that production efforts were not synchronized with actual demand. This discrepancy misled investors regarding the company's anticipated growth and stability.
• - Trends Affecting Revenue: Under Item 303 of Regulation S-K, companies must outline known trends that could materially impact revenues. The lawsuit asserts that Nano-X neglected to mention significant operational cost increases and an accelerating cash burn rate, which could have warned investors of underlying issues.
• - Misrepresentations of Asset Impairment: Previous reports indicated a much healthier status of the company’s manufacturing assets, recording only a minor $0.2 million impairment in earlier years. This created false security among investors regarding the performance of the Korean manufacturing facility.

Ongoing Investigation and Impacts

The lawsuit articulates that when the actual situation regarding the manufacturing was finally disclosed, it starkly contrasted with earlier reports, revealing a need for urgent restructuring costing an estimated $18 million. The decision to abruptly abandon domestic chip production further alarmed shareholders, ultimately leading to the drastic drop in stock value.

Joseph E. Levi, partner at the firm, emphasized the importance of transparency in SEC filings, stating that misleading statements or omissions of critical trends can severely undermine investor trust. “When specific known issues are actively affecting a company's operations, they cannot be glossed over with generic risk language,